The pattern of comorbidities in cancer patients in Lagos, South-Western Nigeria.

Autor: Salako O; Department of Radiotherapy, Lagos University Teaching Hospital, Idi-Araba, Lagos 100254, Nigeria., Okediji PT; Research and Development, Sebeccly Cancer Care, Yaba, Lagos 101212, Nigeria., Habeebu MY; Department of Radiotherapy, Lagos University Teaching Hospital, Idi-Araba, Lagos 100254, Nigeria., Fatiregun OA; Department of Radiotherapy, Lagos State University Teaching Hospital, Ikeja, Lagos 100254, Nigeria., Awofeso OM; College of Medicine, University of Lagos, Akoka, Lagos 100254, Nigeria., Okunade KS; Department of Obstetrics and Gynaecology, College of Medicine, University of Lagos, Lagos 100254, Nigeria., Odeniyi IA; Department of Medicine, Faculty of Clinical Sciences, College of Medicine, University of Lagos, Lagos 100254, Nigeria., Salawu KO; Research and Development, Sebeccly Cancer Care, Yaba, Lagos 101212, Nigeria., Oboh EO; Department of Radiotherapy, University of Benin Teaching Hospital, Benin 300283, Nigeria.
Jazyk: angličtina
Zdroj: Ecancermedicalscience [Ecancermedicalscience] 2018 Jun 13; Vol. 12, pp. 843. Date of Electronic Publication: 2018 Jun 13 (Print Publication: 2018).
DOI: 10.3332/ecancer.2018.843
Abstrakt: Purpose: Comorbidities have been indicated to influence cancer care and outcome, with strong associations between the presence of comorbidities and patient survival. The objective of this study is to determine the magnitude and pattern of comorbidities in Nigerian cancer populations, and demonstrate the use of comorbidity indices in predicting mortality/survival rates of cancer patients.
Methods: Using a retrospective study design, data were extracted from hospital reports of patients presenting for oncology care between January 2015 and December 2016 at two tertiary health facilities in Lagos, Nigeria. Patient comorbidities were ranked and weighted using the Charlson comorbidity index (CCI).
Results: The mean age for the 848 cancer patients identified was 53.9 ± 13.6 years, with 657 (77.5%) females and 191 (22.5%) males. Breast (50.1%), cervical (11.1%) and colorectal (6.3%) cancers occurred most frequently. Comorbidities were present in 228 (26.9%) patients, with the most common being hypertension (20.4%), diabetes (6.7%) and peptic ulcer disease (2.1%). Hypertension-augmented CCI scores were 0 (15.6%), 1-3 (62.1%), 4-6 (21.7%) and ≥7 (0.6%). The mean CCI scores of patients ≤50 years (0.8 ± 0.9) and ≥51 years (3.3 ± 1.2) were significantly different ( p < 0.05). Patients with lower mean CCI scores were more likely to receive chemotherapy (2.2 ± 1.6 versus 2.5 ± 1.9; p < 0.05) and/or surgery (2.1 ± 1.5 versus 2.4 ± 1.7; p < 0.05).
Conclusion: Comorbidities occur significantly in Nigerian cancer patients and influence the prognosis, treatment outcome and survival rates of these patients. There is a need to routinely evaluate cancer patients for comorbidities with the aim of instituting appropriate multidisciplinary management measures where necessary.
Databáze: MEDLINE
Externí odkaz: